NCT03258710 - A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 2, 2017

Primary Completion Date

December 28, 2018

Study Completion Date

November 25, 2019

Conditions

Hepatitis B, Chronic

Interventions

DRUG

Tenofovir Disoproxil Fumarate

Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.

Trial Locations (18)

467-8602

GSK Investigational Site, Aichi

270-1694

GSK Investigational Site, Chiba

790-0024

GSK Investigational Site, Ehime

790-8524

GSK Investigational Site, Ehime

802-0077

GSK Investigational Site, Fukuoka

810-8539

GSK Investigational Site, Fukuoka

830-0011

GSK Investigational Site, Fukuoka

737-0023

GSK Investigational Site, Hiroshima

060-0033

GSK Investigational Site, Hokkaido

080-0024

GSK Investigational Site, Hokkaido

213-8587

GSK Investigational Site, Kanagawa

216-8511

GSK Investigational Site, Kanagawa

862-8655

GSK Investigational Site, Kumamoto

856-8562

GSK Investigational Site, Nagasaki

545-8586

GSK Investigational Site, Osaka

105-8470

GSK Investigational Site, Tokyo

180-8610

GSK Investigational Site, Tokyo

683-0002

GSK Investigational Site, Tottori